- Home
- SSBK vs SLN Comparison
SSBK vs SLN Comparison
Compare SSBK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- SLN
- Stock Information
- Founded
- SSBK 2007
- SLN 1994
- Country
- SSBK United States
- SLN United Kingdom
- Employees
- SSBK N/A
- SLN N/A
- Industry
- SSBK Commercial Banks
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- SLN Health Care
- Exchange
- SSBK Nasdaq
- SLN Nasdaq
- Market Cap
- SSBK 330.0M
- SLN 352.2M
- IPO Year
- SSBK 2021
- SLN N/A
- Fundamental
- Price
- SSBK $34.63
- SLN $5.56
- Analyst Decision
- SSBK Buy
- SLN Strong Buy
- Analyst Count
- SSBK 1
- SLN 4
- Target Price
- SSBK $36.00
- SLN $61.50
- AVG Volume (30 Days)
- SSBK 24.0K
- SLN 439.4K
- Earning Date
- SSBK 01-21-2025
- SLN 03-11-2025
- Dividend Yield
- SSBK 1.04%
- SLN N/A
- EPS Growth
- SSBK 3.86
- SLN N/A
- EPS
- SSBK 3.67
- SLN N/A
- Revenue
- SSBK $94,140,000.00
- SLN $21,773,221.00
- Revenue This Year
- SSBK N/A
- SLN N/A
- Revenue Next Year
- SSBK $11.75
- SLN $104.98
- P/E Ratio
- SSBK $9.29
- SLN N/A
- Revenue Growth
- SSBK 13.56
- SLN N/A
- 52 Week Low
- SSBK $22.13
- SLN $4.82
- 52 Week High
- SSBK $39.16
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- SSBK 55.59
- SLN 33.35
- Support Level
- SSBK $33.05
- SLN $4.82
- Resistance Level
- SSBK $35.28
- SLN $7.87
- Average True Range (ATR)
- SSBK 1.08
- SLN 0.65
- MACD
- SSBK 0.28
- SLN 0.02
- Stochastic Oscillator
- SSBK 85.24
- SLN 22.70
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.